tbuckley/cabot-search huggingface dataset:
Cellular Responses to Oxidative Stress: The [Ah] Gene Battery As a Paradigm
Authors: Daniel W. Nebert, Daniel D. Petersen, Albert J. Fornace
Journal: Environmental Health Perspectives (1990)

A major source of oxidative stress in animals is plant stress metabolites, also termed phytoalexins. The aromatic hydrocarbon-responsive [Ah] gene battery is considered here as a model system in which we can study metabolically coordinated enzymes that respond to phytoalexin-induced oxidative stress. In the mouse, the [Ah] battery comprises at least six genes: two Phase I genes, CYP1A1 and CYP1A2; and four Phase II genes, Nmo-1, Aldh-1, Ugt-1, and Gt-1. All six genes appear to be regulated positively by inducers such as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and other ligands of the Ah receptor. In the absence of foreign inducer, the control of Nmo-1 gene expression is independent of the control of CYP1A1 and CYP1A2 gene expression. The radiation deletion homozygote c14CoS/c14CoS mouse is lacking about 1.1 centiMorgans of chromosome 7. Although having no detectable CYP1A1 or CYP1A2 activation, the untreated c14CoS/c14CoS mouse exhibits markedly elevated transcripts of the Nmo-1 gene and three growth arrest- and DNA damage-inducible (gadd) genes. These data suggest that the missing region on chromosome 7 in the c14CoS/c14CoS mouse contains a gene(s), which we propose to call Nmo-1n, encoding a trans-acting factor(s) that is a negative effector of the Nmo-1 and gadd genes. The three other [Ah] battery Phase II genes behave similarly to Nmo-1 in the c14CoS/c14CoS mouse. This coordinated response to oxidative stress and DNA damage, by way of the release of a mammalian battery of genes from negative control, bears an interesting resemblance to the SOS response in bacteria.
Hypnosis in Modern Medicine.
Journal: JAMA (1953)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Differentiation of Two Genetically Specific Types of Depression by the Response to Anti-Depressants
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
RECENT ADVANCES IN PERNICIOUS ANEMIA
Journal: JAMA (1927)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Levothyroxine Therapy
Authors: Susan J. Mandel
Journal: Annals of Internal Medicine (1994)

Letters1 April 1994Levothyroxine TherapySusan J. Mandel, MD, Gregory A. Brent, MD, and P. Reed Larsen, MDSusan J. Mandel, MDHarvard Medical School; Brigham and Women's Hospital; 75 Francis Street; Boston, MA 02115Search for more papers by this author, Gregory A. Brent, MDHarvard Medical School; Brigham and Women's Hospital; 75 Francis Street; Boston, MA 02115Search for more papers by this author, and P. Reed Larsen, MDHarvard Medical School; Brigham and Women's Hospital; 75 Francis Street; Boston, MA 02115Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-120-7-199404010-00018 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:We agree that the benefits of levothyroxine therapy for all patients with solitary thyroid nodules have not been clearly established. In one randomized, controlled study, the nodule volume decreased significantly from baseline in those patients receiving levothyroxine but not placebo [1]. Similar results were not achieved in other studies discussed. However, as Dr. Leinung points out, TSH-suppressive therapy may forestall or prevent surgery with its morbidity and cost in selected patients. Because such levothyroxine-responsive nodules cannot be identified by pretreatment variables [2], we have attempted to devise a rational approach to therapy. To minimize the potential morbidity associated ...References1. Gharib H, James EM, Charboneau JW, Naessens JM, Offord KP, Gorman CA. Suppressive therapy with levothyroxine for solitary thyroid nodules. N Engl J Med. 1987; 317:70-5. Google Scholar2. Cheung PS, Lee JM, Boey JH. Thyroxine suppressive therapy of benign solitary thyroid nodules: a prospective randomized study. World J Surg. 1989; 13:818-22. Google Scholar3. Mazzaferri EL. Management of a solitary thyroid nodule. N Engl J Med. 1993; 328:553-9. Google Scholar4. Lewander W. Thyroid hormone overdose. Clinical Toxicology Review. 1984; v.6. Google Scholar5. McLean M, Kirkwood I, Epstein M, Jones B, Hall C. Cation-exchange resin and inhibition of intestinal absorption of thyroxine. Lancet. 1993; 341:1286. Google Scholar Author, Article, and Disclosure InformationAuthors: Susan J. Mandel, MD; Gregory A. Brent, MD; P. Reed Larsen, MDAffiliations: Harvard Medical School; Brigham and Women's Hospital; 75 Francis Street; Boston, MA 02115 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 April 1994Volume 120, Issue 7Page: 619-620KeywordsDrug absorptionDrugsMorbiditySodiumSurgeryThyroidThyroid hormonesThyroid-stimulating hormoneThyroxine ePublished: 15 August 2000 Issue Published: 1 April 1994 Copyright & PermissionsCopyright © 1994 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Sterile microenvironment in prevention of wound infection
Authors: J M Scott, J. McLauchlan, H G Smylie
Journal: BMJ (1982)

A prospective controlled trial was carried out to assess the effect of using a wound isolator on reducing post- operative infection.A total of 291 patients undergoing hip pinning for fractures of the neck of femur entered the trial and were allocated at random to have their wound contained in a wound isolator (study group) or dressed with a standard gamma-irradiated adhesive dressing (control group).The bacteriological flora of the patient was monitored before, during, and after operation and that of the ward before and after.No significant difference was found in the flora of the wards in which the patients were nursed.On several occasions the source of the infective organism was traced to the ward but never to the theatre.The isolator prevented direct contamination and airborne cross-infection of the wound and appreciably reduced the rate of infection.
Higher Medical Education; the True Interest of the Public and the Profession.
Journal: JAMA (1894)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Complications of Prolonged Pregnancies
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract A118: An open label pilot study of NovoTTF Therapy concomitant with gemcitabine for front-line therapy of advanced pancreatic adenocarcinoma (NCT01971281)
Authors: Uri Weinberg, Eilon Kirson, Ori Farber, Yoram Palti
Journal: Cancer Research (2015)

Abstract Background: NovoTTF Therapy is a non-invasive, anti-mitotic treatment modality, based on low intensity alternating electric fields. Tumor Treating Fields (TTFields) interfere with two steps during mitosis: The formation of the mitotic spindle (metaphase), and the translocation of charged organelles (anaphase). TTFields inhibit proliferation of pancreatic cell lines in vitro, and inhibit pancreatic tumor growth in vivo, alone and in combination with gemcitabine. NovoTTF Therapy applied to the brain in recurrent GBM patients demonstrated an anti-tumoral effect with minimal toxicity and better quality of life, compared to chemotherapy (Stupp et al, 2012). Being a regional treatment, TTFields can potentially inhibit the primary tumor as well as major metastatic sites of pancreatic adenocarcinoma. Methods: Objectives: the current trial is designed to study the safety, tolerability and efficacy of NovoTTF therapy applied to the abdomen concomitant to the standard care gemcitabine treatment, in patients suffering from advanced pancreatic adenocarcinoma. Endpoints: severity and frequency of adverse events associated with the experimental treatment (primary), progression free survival (PFS), 6-month PFS rate, overall survival, overall response rate, compliance with NovoTTF Therapy (secondary) Treatments: Gemcitabine 1000 mg/m2 over 30 minute infusion once weekly for up to 7 weeks, followed by a week rest from treatment. Subsequent cycles will consist of once weekly infusions on days 1, 8, 15 every 28 days. Continuous NovoTTF Therapy at a frequency of 150 kHz will be administered to the abdomen, in order to cover the region of primary tumor and main metastatic sites. The fields will be applied in two perpendicular directions at a maximal intensity of 1414 mA RMS, using highly insulated Transducer Arrays connected to a portable, battery-operated electric field generator. TTFields will be administered for at least 18 hours a day until radiological disease progression. Major eligibility criteria: unresectable, pathologically confirmed, locally advanced/metastatic pancreatic adenocarcinoma, measurable/assessable disease, ECOG score 0-1, no prior chemotherapy or radiation, no implantable electronic medical devices. Citation Format: Uri Weinberg, Eilon Kirson, Ori Farber, Yoram Palti. An open label pilot study of NovoTTF Therapy concomitant with gemcitabine for front-line therapy of advanced pancreatic adenocarcinoma (NCT01971281). [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer: Innovations in Research and Treatment; May 18-21, 2014; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2015;75(13 Suppl):Abstract nr A118.
Research Activist
Journal: JAMA (2002)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Massachusetts Medical Society
Authors: John Figgis Jewett
Journal: New England Journal of Medicine (1956)

COMMITTEE ON MATERNAL WELFAREAnesthetic DeathA twenty-six-year-old gravida II, para I, had a normal prenatal course and went into spontaneous active labor about three weeks before term. She died less than an hour after admission.She was admitted to the hospital in active labor at about 3:00 a.m., when the cervix was fully dilated, with the vertex in the left occipital anterior position. There was scarcely time for obstetric preparation when the membranes ruptured spontaneously fifteen minutes later, and the patient was rushed to the delivery room, where open drop ether was started with the patient in lithotomy position . . .
Contents
Authors: Walid Kaplan, Agneta Sunehag, Harry Dao, Morey Haymond, Revi Mathew, Daniel Byrne, Macrae Linton, Douglas Vaughan, Sergio Fazio, William Russell 733 25-Hydroxyvitamin, Laura Carbone, E Rosenberg, Elizabeth Tolley, Michael Holick, Thomas Hughes, Mitchell Watsky, Karen Barrow, Tai Chen, Nathaniel Wilkin, Syamal Bhattacharya, John Dowdy, Robert Sayre, Karl Weber, Keiichi Koshinaka, Akiko Sano, Kirsten Howlett, Takako Yamazaki, Maiko Sasaki, Kei Sakamoto, Kentaro Kawanaka, Paul Arciero, Christopher Gentile, Roger Pressman, Meghan Everett, Michael Ormsbee, Jeff Martin, Jason Santamore, Liza Gorman, Patricia Fehling, Matthew Vukovich, Bradley Nindl
Journal: Metabolism (2008)
QT dynamics as an independent predictor of mortality in CHF patients Curnier Daniel, Pathak Atul, Fourcade Joelle, Bousquet Marc, Fauvel Jean-Marie, Bounhoure Jean-Pierre, Montastruc Jean-Louis, Galinier Michel. CHU Rangeuil, Toulouse, France, INSERM U317, Toulouse, France
Journal: Journal of the American College of Cardiology (2001)
Retracted
Authors: Samah Elsaadi, Kristine Misund, Pegah Abdollahi, Esten Nymoen Vandsemb, Siv Helen Moen, Anna Kusnierczyk, Geir Slupphaug, Therese Standal, Anders Waage, Tobias S Slørdahl, Even Rustad, Anders Sundan, Carl Hay, Alwin G Schuller, Alexandra Borodovsky, Eline Menu, Magne Børset, Anne Marit Sponaas
Journal: Journal for ImmunoTherapy of Cancer (2020)
Phase Ib study of ficlatuzumab (formerly AV-299), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb) in combination with gefitinib (G) in Asian patients (pts) with NSCLC.
Authors: E. Tan, K. Park, W. T. Lim, M. Ahn, Q. S. Ng, J. S. Ahn, D. S. Tan, J. Sun, J. Jac, M. Han, F. C. Payumo, M. Credi, K. McKee, M. M. Cotreau, P. Bhargava, W. Slichenmyer
Journal: Journal of Clinical Oncology (2011)

7571 Background: Ficlatuzumab is a humanized anti-HGF IgG1 MAb that inhibits activation of the c-Met receptor by neutralizing its only known natural ligand, HGF. HGF/c-Met pathway activation has been implicated in EGFR TKI resistance in NSCLC. In a phase I trial in pts with solid tumors, ficlatuzumab was well tolerated up to the maximum tested dose of 20 mg/kg both as a single agent and in combination with erlotinib (150 mg/day). Methods: Two dose levels of ficlatuzumab (10 and 20 mg/kg) in combination with 250 mg G were evaluated for safety, tolerability, and recommended phase II dose (RP2D). Enrolled pts were Asians with unresectable NSCLC, performance status (PS) ≤2, and adequate organ function. Ficlatuzumab was given IV every 2 weeks and G was given PO once daily in 28 day cycles. RP2D was defined as the highest dose at which ≤ 1 of 6 pts experienced a dose-limiting toxicity (DLT) during Cycle 1. At RP2D, 6 additional pts were enrolled. Pts were evaluated every 4 weeks for response using RECIST 1.1. Results: 15 pts enrolled: 5M/10F; median age 60 yrs, range 46-76 yrs; ECOG PS 0 (4 pts) or 1 (11 pts); median number of prior therapies was 3, range 1-5. Ten pts were EGFR TKI pretreated, 5 pts were EGFR TKI naïve. Three pts received ficlatuzumab 10 mg/kg and G 250 mg; 12 pts received ficlatuzumab 20 mg/kg and G 250 mg. No DLTs were observed in the dose-escalation cohorts. Most frequent treatment-emergent adverse events (AEs): dermatitis acneiform (53%), cough (40%), decreased appetite (33%), diarrhea (33%), paronychia (33%), edema (27%), drug hypersensitivity (27%), and fatigue (27%). Grade 3/4 related AEs: diffuse alveolar damage, paronychia, edema, and rash. RP2D is ficlatuzumab 20 mg/kg IV every 2 weeks with G 250 mg PO daily. Among 12 pts in the 20 mg/kg cohort: 5 pts had PR (all in EGFR TKI naïve), 4 had SD, and 3 had PD. Median duration of treatment: 12 weeks (range 3.6-40). Conclusions: The combination of ficlatuzumab and G was well tolerated and demonstrated clinical activity in pts with NSCLC. A phase II open-label, randomized, first line trial is ongoing in Asian pts with lung adenocarcinoma (never- or former light-smokers) comparing ficlatuzumab + G vs G alone.
Commentaries
Authors: C C Harling
Journal: British Journal of Sports Medicine (1997)

This interesting paper will provide food for thought for all physiotherapy, medical, and coaching staff involved in professional football.It develops an interesting theme that chronic and overuse injury are an occupational hazard to the professional footballer, and thus under Health and Safety Law it is the responsibility of the professional clubs to provide a health surveillance programme to identify these inju- ries in the early stages and manage them appropriately before exacerbation or chronic injury occurs.
Mammographic Screening
Authors: Devra Lee Davis
Journal: JAMA (1994)

Since 1987, the United States has stood alone among major developed countries in having encouraged asymptomatic women under 50 years of age to undergo screening mammography, although US mortality rates for women these ages continue to mirror those of other Western countries.<sup>1</sup>Recent reports in<i>JAMA</i>and elsewhere compel a reexamination of this policy. Diagnostic mammographic evaluation is indicated at any age if a woman has a lump or other signs of disease. In contrast to diagnostic assessments, screening mammography is a routine measure seeking to detect latent disease in asymptomatic women, in order to provide treatment, which may increase the likelihood of a cure.<sup>2</sup>
Comprehensive analysis of cancer-related genes and AAV/hepatitis B virus integration into genome on development of hepatocellular carcinoma in patients with prior hepatitis B virus infection
Authors: Fukiko Kawai-Kitahata, Yasuhiro Asahina, Sei Kakinuma, Miyako Murakawa, Sayuri Nitta, Masato Miyoshi, Ayako Sato, Jun Tsuchiya, Taro Shimizu, Eiko Takeichi, Mina Nakagawa, Yasuhiro Itsui, Seishin Azuma, Shinji Tanaka, Minoru Tanabe, Shinya Maekawa, Nobuyuki Enomoto, Mamoru Watanabe
Journal: Journal of Hepatology (2020)